Spark NIR™ 685 anti-human CD62L
Description
CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells. CD62L binds to carbohydrates present on certain glycoforms of CD34, glycam-1, and MAdCAM-1 and with a low affinity to anionic oligosaccharide sequences related to sialylated Lewis X (sLex, CD15s) through its C-type lectin domain. CD62L is important for the homing of naïve lymphocytes to high endothelial venules in peripheral lymph nodes and Peyer's patches. It also plays a role in leukocyte rolling on activated endothelial cells.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
* Spark NIR™ 685 has a maximum excitation of 665 nm and a maximum emission of 685 nm.
References
- Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Kishimoto TK, et al. 1990. Proc. Natl. Acad. Sci. USA 87:2244. (WB, Block)
- Jutila M, et al. 2002. J. Immunol. 169:1768. (WB)
- Tamassia N, et al. 2008. J. Immunol. 181:6563. (FC) PubMed
- Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
- Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
- Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
- Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- Koenig JM, et al. 1996. Pediatr. Res. 39:616. (WB)
- Shi C, et al. 2011. J. Immunol. 187:5293. (FC) PubMed
- Burges M, et al. 2013. Clin Cancer Res. 19:5675. PubMed
- Cash JL, et al. 2013. EMBO Rep. 14:999. (FC) PubMed